Ensitrelvir 是首个口服有效的、非共价的、非肽的SARS-CoV-2 3CL蛋白酶抑制剂，IC50为13 nM。

Ensitrelvir is an orally active inhibitor of SARS-CoV-2 3CL protease with IC50 of 13 nM.

The EC50 values for SARS-CoV and MERS-CoV were 0.21 and 1.4 μM respectively. In a cytopathic effect (cpe)-inhibition assay of SARS-CoV-2 infected VeroE6/TMPRSS2 cells, Ensitrelvir shows the EC50 values are approximately 0.4 μM for both wild-type virus and Alpha, Beta, Gamma and Delta variants[1].

Ensitrelvir inhibits intrapulmonary replication of SARS-CoV-2 in mice in a dose-dependent manner[1].

2647530-73-0

DMSO:160 mg/mL (300.82 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years